SG Americas Securities
PSTX

SG Americas Securities’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

SG Americas Securities’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,623
Closed -$294K – 3851
2024
Q4 		$294K Buy
30,623
+6,206
+25% +$32.4K ﹤0.01% 1818
2024
Q3 		$70K Buy
+24,417
New +$75.6K ﹤0.01% 3172
2024
Q2 		– Sell
-28,511
Closed -$91K – 3403
2024
Q1 		$91K Sell
28,511
-8,464
-23% -$28.2K ﹤0.01% 2592
2023
Q4 		$124K Buy
36,975
+2,049
+6% +$5.28K ﹤0.01% 2587
2023
Q3 		$83K Buy
34,926
+3,910
+13% +$8.19K ﹤0.01% 2842
2023
Q2 		$55K Buy
31,016
+7,056
+29% +$18K ﹤0.01% 2131
2023
Q1 		$74K Buy
+23,960
New +$144K ﹤0.01% 2997
2021
Q4 		– Sell
-21,323
Closed -$155K – 3888
2021
Q3 		$155K Buy
+21,323
New +$183K ﹤0.01% 3405

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SG Americas Securities's PSTX Position: Q1 2025 in Review

SG Americas Securities sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 30,623 shares — an estimated $294K sold.

SG Americas Securities first reported a position in PSTX in Q3 2021 and held it in 8 quarters. The position peaked at $294K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • SG Americas Securities reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • SG Americas Securities sold 30,623 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $294K.
  • SG Americas Securities first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
  • SG Americas Securities's Poseida Therapeutics, Inc. Common Stock position peaked at $294K in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on SG Americas Securities's 13F filing for Q1 2025, filed 15 Apr 2025.